3D-printed Laponite/alginate hydrogel-based suppositories as innovative platforms for AT-MSC secretome delivery in
Elena Munoz-Perez1, Manoli Igartua2, Edorta Santos-Vizcaino2
1NanoBioCel Research Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-Gasteiz, Spain; Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain.
Abstract:
The secretome of Mesenchymal Stromal Cells (MSCs) has demonstrated effectiveness in the treatment of Inflammatory Bowel Disease (IBD), offering a safer and more predictable alternative to the direct administration of MSCs. While parenteral administration is common, rectal delivery of the secretome provides targeted treatment for localized conditions such as ulcerative colitis and proctitis. Alginate-Laponite 3D-printed suppositories (Alg-Lap 3DPS) have shown a remarkable versatility in their ability to encapsulate and deliver therapeutic agents during previous studies. These formulations are also adaptable in the release of molecules with different physicochemical properties, and a Bovine Serum Albumin (BSA) displacement strategy has been proposed in order to promote their disintegration and controlled release. As such, these 3DPS formulations represent highly versatile pharmaceutical forms, enabling the rectal delivery of diverse molecules with controlled release characteristics. In this study, we combined the therapeutic potential of Adipose tissue derived-MSCs-secretome (AT-S) with the versatility and efficacy of Alg-Lap 3DPS. Herein, we demonstrate that these formulations are well-suited for the encapsulation and release of AT-S, confirming their ability to release bioactive factors from AT-S such as Galectin-9 upon applying the displacement strategy. Moreover, we validate the bioactivity of the released factors in vitro by testing their effects on pro-inflammatory M1-polarized macrophages. Notably, this study not only confirms the anti-inflammatory capacity of the AT-S-loaded 3DPS in vitro but also aims to elucidate the underlying mechanisms driving these immunomodulatory effects, revealing the inherent immunomodulatory capacity of the Alg-Lap matrices themselves in M1 macrophages and establishing the AT-S-loaded 3DPS formulations as innovative therapeutic approaches for the treatment of IBD.
More Related Videos
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
10:33Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD
